WINDTREE THERAPEUTICS INC /DE/ Net Income (Loss) Available to Common Stockholders, Basic
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Net Income (Loss) Available to Common Stockholders, Basic of -$28.94 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2025-11-19
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$28.94M.
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$14.92M.
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$5.04M, a 149.35% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was $68.00K.
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for fiscal 2024 was -$5.49M.
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for fiscal 2023 was -$20.29M.
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for fiscal 2019 was -$27.48M.
- WINDTREE THERAPEUTICS INC /DE/ net income (loss) available to common stockholders, basic for fiscal 2018 was -$34.76M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | -$28.94M 10-Q · filed 2025-11-19 | -$43.86M derived: sum of 2 quarters · filed 2025-11-19 | -$48.90M 10-Q · filed 2025-11-19 | -$48.83M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2025-06-30 | -$14.92M 10-Q · filed 2025-08-19 | -$19.96M 10-Q · filed 2025-08-19 | -$19.89M derived: sum of 3 quarters · filed 2025-08-19 | -$23.64M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2025-03-31 | -$5.04M 10-Q · filed 2025-05-15 | -$4.97M derived: sum of 2 quarters · filed 2025-05-15 | -$8.72M derived: sum of 3 quarters · filed 2025-11-19 | -$20.75M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$3.68M derived: sum of 2 quarters · filed 2025-11-19 | -$15.71M derived: sum of 3 quarters · filed 2025-11-19 | -$5.49M 10-K · filed 2025-04-15 | ||
| 2024-09-30 | -$3.75M 10-Q · filed 2025-11-19 | -$15.77M derived: sum of 2 quarters · filed 2025-11-19 | -$5.55M 10-Q · filed 2025-11-19 | -$10.71M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | -$12.02M 10-Q · filed 2025-08-19 | -$1.80M 10-Q · filed 2025-08-19 | -$6.96M derived: sum of 3 quarters · filed 2025-08-19 | -$11.38M derived: sum of 4 quarters · filed 2025-08-19 | ||
| 2024-03-31 | $10.22M 10-Q · filed 2025-05-15 | $5.07M derived: sum of 2 quarters · filed 2025-05-15 | $640.00K derived: sum of 3 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$9.58M derived: sum of 2 quarters · filed 2025-04-15 | -$20.29M 10-K · filed 2025-04-15 | |||
| 2023-09-30 | -$4.42M 10-Q · filed 2024-11-26 | -$15.14M 10-Q · filed 2024-11-26 | ||||
| 2019-12-31 | -$27.48M 10-K · filed 2020-04-03 | |||||
| 2018-12-31 | -$23.27M 10-K · filed 2020-04-03 | -$27.19M derived: sum of 2 quarters · filed 2020-04-03 | -$30.24M derived: sum of 3 quarters · filed 2020-04-03 | -$34.76M 10-K · filed 2020-04-03 | ||
| 2018-09-30 | -$3.93M 10-K · filed 2020-04-03 | -$6.98M derived: sum of 2 quarters · filed 2020-04-03 | -$11.49M 10-Q · filed 2018-11-14 | -$9.02M derived: sum of 4 quarters · filed 2020-04-03 | ||
| 2018-06-30 | -$3.05M 10-K · filed 2020-04-03 | -$7.56M 10-Q · filed 2018-08-14 | -$5.09M derived: sum of 3 quarters · filed 2020-04-03 | -$12.77M derived: sum of 4 quarters · filed 2020-04-03 | ||
| 2018-03-31 | -$4.51M 10-K · filed 2020-04-03 | -$2.04M derived: sum of 2 quarters · filed 2020-04-03 | -$9.72M derived: sum of 3 quarters · filed 2020-04-03 | -$17.00M derived: sum of 4 quarters · filed 2020-04-03 | ||
| 2017-12-31 | $2.47M 10-K/A · filed 2019-04-23 | -$5.20M derived: sum of 2 quarters · filed 2019-04-23 | -$12.49M derived: sum of 3 quarters · filed 2019-04-23 | -$24.82M 10-K/A · filed 2019-04-23 | ||
| 2017-09-30 | -$7.68M 10-K/A · filed 2019-04-23 | -$7.36M 10-Q · filed 2017-11-14 | -$14.96M derived: sum of 2 quarters · filed 2019-04-23 | -$27.29M 10-Q · filed 2018-11-14 | -$26.97M 10-Q · filed 2017-11-14 | -$33.89M derived: sum of 4 quarters · filed 2019-04-23 |
| 2017-06-30 | -$7.28M 10-K/A · filed 2019-04-23 | -$19.61M 10-Q · filed 2018-08-14 | -$26.21M derived: sum of 3 quarters · filed 2019-04-23 | -$34.58M derived: sum of 4 quarters · filed 2019-04-23 | ||
| 2017-03-31 | -$12.33M 10-K/A · filed 2019-04-23 | -$18.93M derived: sum of 2 quarters · filed 2019-04-23 | -$27.29M derived: sum of 3 quarters · filed 2019-04-23 | -$37.92M derived: sum of 4 quarters · filed 2019-04-23 | ||
| 2016-12-31 | -$6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17 | -$14.96M derived: sum of 2 quarters · filed 2018-04-17 | -$25.59M derived: sum of 3 quarters · filed 2018-04-17 | -$39.49M 10-K · filed 2018-04-17 | ||
| 2016-09-30 | -$8.36M 10-Q · filed 2017-11-14 | -$18.99M derived: sum of 2 quarters · filed 2017-11-14 | -$32.89M 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | -$10.62M 10-Q · filed 2017-08-21 | -$24.52M 10-Q · filed 2017-08-21 | ||||
| 2016-03-31 | -$13.90M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |